Blog
30 March 2020
COVID-19 and Virtual Trials: What does the FDA’s guidance mean for drug development?
The FDA have released guidance urging clinical trials to go virtual where possible in response to the COVID-19 pandemic – so what are the best methods for ensuring patient safety and trial integrity during this transition? In this article, we will discuss some of the important aspects to consider when taking a therapeutic trial from the clinic to the patient’s home.
The full FDA Guidance on Conduct of Clinical Trials of Medical Products During the COVID-19 Pandemic is available here.
Read on
25 March 2020
What are the biological mechanisms behind chemotherapy-associated cognitive impairment?
Despite chemotherapy-associated cognitive impairment (CACI, aka chemobrain) affecting 75% of all cancer survivors, little is understood about the mechanisms underlying the disorder. In efforts to address this research gap, Prof Alexandre Chan from the University of California, Irvine used CANTAB to conduct an evaluation of DNA Methyltransferase 1 (DNMT1) Single Nucleotide Polymorphisms and Chemotherapy-Associated Cognitive Impairment. Read on to find out the results.
Read on
19 March 2020
How does an alcohol hangover affect cognition?
We caught up with Lydia Devenney from Letterkenny Institute of Technology to find out why she chose CANTAB to assist her research into investigating attention, memory functioning, and mood in a natural setting with real‐life alcohol consumption levels.
Read on
28 February 2020
How does cognition play a role in rare diseases?
Cambridge Cognition's Jemma Clark shares her insight into how cognitive function can be affected in certain rare diseases and why it is important to include cognitive tests in rare disease trials.
Read on
25 February 2020
Modelling associations between neurocognition and functional course in young people with emerging mental disorders: a longitudinal cohort study
We caught up with Jacob Crouse from the University of Sydney’s Brain and Mind Centre to discuss his research into key factors that underpin mental health disorders in young people, with a view to improving outcomes.
Read on
29 January 2020
Why does PSYSCAN use CANTAB?
PSYSCAN is a global project, which aims to develop a neuroimaging-based tool that will help healthcare professionals to address key clinical issues for patients with psychotic disorders. We caught up with study coordinator – Aimée Westerveld – to find out more about the role of CANTAB in the project.
